NCT04025541not applicablerecruiting

Analysis of Circulating Tumor Markers in Blood

Institut du Cancer de Montpellier - Val d'Aurelle

ClinicalTrials.gov

992

Enrollment · estimated

Countries · 2 sites

2026-05

Primary completion

1 yr ago

Record updated

Commercial relevance

Trial record references molecular eligibility required, ctDNA / liquid biopsy referenced, resistance-monitoring language.

Molecular eligibility requiredctDNA / liquid biopsyResistance monitoring

Change timeline

No changes detected yet. The first refresh records a baseline snapshot; subsequent refreshes generate field-level changes.

Signals from this trial

New trial
68/100
Opportunity
New not applicable trial NCT04025541 posted by Institut du Cancer de Montpellier - Val d'Aurelle: "Analysis of Circulating Tumor Markers in Blood".
ClinicalTrials.gov record updated 524 days ago.

Eligibility — raw, for validation

Inclusion Criteria:

1. Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage,
2. Man or woman ≥ 18 years,
3. Obtaining of the informed consent signed before any procedure of specific preselection on approval.

Exclusion Criteria:

1. Private persons of freedom or under guardianship,
2. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
3. Pregnant woman and/or breast-feeding,
4. Unaffiliated patient to Social Protection System,